Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo, PFI, Granutec begin private label cimetidine/ranitidine promos to trade.

This article was originally published in The Tan Sheet

Executive Summary

PERRIGO, PFI, GRANUTEC START GENERIC CIMETIDINE/RANITIDINE PROMOS, beginning with the first big push to the trade at the Private Label Manufacturer's Association annual trade show in Chicago Nov. 16-19. The three generic drug companies are the first to begin marketing the next big private label OTC, the H2 antagonists, in anticipation of the termination of marketing exclusivity and the companies receiving ANDA approvals for generic versions of the drugs. Tagamet HB 200 (cimetidine) from SmithKline Beecham loses exclusivity June 19, and Glaxo Wellcome's Zantac 75 (ranitidine) loses marketing exclusivity Dec. 19, 1998.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel